New chemotherapy compared with docetaxel for advanced breast cancer
Treatments studied
Part of Cancer clinical trials.
This trial compares a new experimental drug (HB1801) with the standard chemotherapy docetaxel (Taxotere) for people with advanced breast cancer. It aims to see if the new drug works better or has fewer side effects.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have breast cancer that has spread (metastatic) or cannot be removed by surgery.
- Your breast cancer is HER2-negative (a specific protein test result).
- You have at least one measurable tumor that is not in the brain.
- You are generally well enough to be up and about (able to do light activities).
- You have not previously gotten worse on taxane chemotherapy (like docetaxel) for advanced breast cancer.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial compares a new chemotherapy drug (called HB1801) to the standard drug docetaxel (Taxotere) for advanced breast cancer. The goal is to see if the new drug works as well and is as safe as the standard one. If you qualify, you would receive one of these treatments, which may help shrink or slow the growth of your cancer.
This study tests a new combination of targeted therapies (HB1801 with trastuzumab and pertuzumab) plus chemotherapy for people with HER2-positive breast cancer that has spread or come back. It aims to see if this treatment helps shrink tumors or slow their growth.
This trial compares two different chemotherapy combinations (one with a newer type of paclitaxel called polymeric micelles, plus an immunotherapy drug called adebelimab) against a standard taxane plus HP regimen, as first-line treatment for advanced HER2-positive breast cancer. The goal is to see if the new combination works better at controlling the cancer.
This trial compares two different drug combinations given before surgery to shrink HER2-positive breast cancer tumors. The goal is to see which combination works better and has fewer side effects.
This trial tests a new medicine called TQB2102 against the standard combination of chemotherapy (docetaxel) plus two targeted therapies (trastuzumab and pertuzumab) for people with HER2-positive breast cancer that has come back or spread. The goal is to see if the new treatment works better and has fewer side effects.
This trial compares two combinations of drugs given before surgery to shrink HER2-positive breast cancer. One uses a new experimental drug (TQB2102) and the other uses standard treatments. The goal is to see which works better at reducing the cancer before surgery.
Hear when a new HER2-Negative Advanced Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.